Study of serum adenosine deaminase levels in head and neck malignancies
DOI:
https://doi.org/10.18203/issn.2454-5929.ijohns20204634Keywords:
Adenosine deaminase, Malignancy, Diagnostic, BiomarkerAbstract
Background: Head and neck malignancies are the malignancies occurring at various sites like scalp, ear, nose and paranasal sinuses, nasopharynx, oral cavity, oropharynx, hypopharynx, larynx, and salivary glands. There are various biomarkers which aid in early diagnosis and management of head and neck malignancies. In order to study various parameters aiding in early diagnosis, this study has been taken up to estimate serum adenosine deaminase levels among these patients.
Methods: Eighty-eight clinically diagnosed head and neck malignancy patients of both genders were included in this study on simple random basis. After obtaining the written informed consent from the patient, a peripheral venous sample of blood was taken and serum ADA levels were estimated. Data was analyzed using IBM SPSS Version 22.
Results: Serum ADA levels are found to be statistically significant with respect to various stages of head and neck malignancies including malignancy of unknown origin. Mean ADA level in this study was 30.33 IU/l. Mean ADA levels in MUO, primary tumor with neck secondaries were 37 IU/l, 38.7 IU/l respectively. Mean ADA levels in patients with primary tumor without neck secondaries was 27.9 IU/l.
Conclusions: The Serum ADA levels among head and neck malignancy patients including MUO is a simple, inexpensive diagnostic biomarker enzyme which is easy and rapid to estimate. This study emphasizes on using Serum ADA levels as a prognostic indicator among head and neck malignancies who are on various modalities of treatment.
Metrics
References
Pai SI, Westra WH. Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol. 2009;4:49-70.
Kapil U, Singh P, Bahadur S, Dwivedi SN, Singh R, Shukla N. Assement of risk factors in laryngeal cancer in India: a case control study. Asian Pac J Cancer Prev. 2005;6(2):202-07.
Ayude D, Gacio G, Páez De La CM, Pallas E, Martínez-Zorzano V, De Carlos A, et al. Combined use of established and novel tumour markers in the diagnosis of head and neck squamous cell carcinoma. Oncol Rep. 2003;10(5):1345-50.
Bansal SK, Singh RP, Narang RK, Joshi LD, Bansal AB, Agrawal AK. Serum ddenosine deaminase in pulmonary tuberculosis, malignancy and non-tubercular respiratory diseases. Indian J Chest Dis Allied Sci. 1991;33(4):189-93.
Satyanarayan U. Biochemistry. Calcutta: Calcutta Books and Allied (P) Ltd; 2001.
Hovi T, Smyth JF, Allison AC, Williams SC. Role of adenosine deaminase in lymphocyte proliferation. Clin Exp Immunol. 1976;23(3):395-403.
Moriwaki Y, Yamamoto T, Higashino K. Enzymes involved in purine metabolism-a review of histochemical localization and functional implications. Histol Histopathol. 1999;14(4):1321-40.
Canbolat O, Durak I, Cetin R, Kavutcu M, Demirci S, Ozturk S. Activities of adenosine deaminase, 5’-nucleotidase, guanase, and cytidine deaminase enzymes in cancerous and non-cancerous human breast tissues. Breast Cancer Res Treat. 1996;37(2): 189-93.
Raczynska J, Jonas S, Krawczynski J. Diagnostic value of adenosine deaminase in some liver diseases. Clinica Chimica Acta. 1966;13(2):151-4.
Kate J, Van den Ingh H, Khan P, Bosman F. Adenosine deaminase complexing protein (ADCP) immunoreactivity in colorectal adenocarcinoma. Int J Cancer. 1986;37(4):479-85.
Giusti G. Adenosine deaminase. In: Bergmeyer HV, eds. Methods of enzymatic analysis. 2nd ed. New York: New York Academic Press; 1974.
Bahrami A, Hassanian S, Khazaei M, Hasanzadeh M, Shahidsales S, Maftouh M, et al. The therapeutic potential of targeting tumor microenvironment in breast cancer: rational strategies and recent progress. J Cell Biochem. 2017;119(1):111-22.
Bahrami A, Khazaei M, Hassanian S, Shahidsales S, Joudi-Mashhad M, Maftouh M, et al. Targeting the tumor microenvironment as a potential therapeutic approach in colorectal cancer: Rational and progress. J Cell Physiol. 2017;233(4):2928-36.
Franco R, Casado V, Ciruela F, Saura C, Mallol J, Canela E, et al. Cell surface adenosine deaminase: Much more than an ectoenzyme. Prog Neurobiol. 1997;52(4):283-94.
Linden J. Adenosine metabolism and cancer focus on adenosine downregulates DPPIV on HT-29 colon cancer cells by stimulating protein tyrosine phosphatases and reducing ERK1/2 activity via a novel pathway. Am J Physiol Cell Physiol. 2006; 291(3):C405-6.
Pragathi P, Bharath KP, Amar KP, Reddy RM, Sravani V, Neeraja J, et al. Evaluation of serum adenosine deaminase and 5’-nucleotidase activities as probable markers in ovarian cancer. Indian J Clin Biochem. 2005;20(2):195-7.
Camici M, Tozzi MG, Allegrini S, Sanfilippo O, Diadone MG, Marco C, et al. Purine salvage enzyme activities in normal and neoplastic human tissues. Cancer Biochem Biophys. 1990;11(3):201-9.
Kelgandre D, Pathak J, Patel S, Ingale P, Swain N. Adenosine deaminase - a novel diagnostic and prognostic biomarker for oral squamous cell carcinoma. Asian Pac J Cancer Prev. 2016;17(4): 1865-8.
Suchitra MM, Reddy PE, Muni SG, Bitla A, Ramesh B, Srinivasa RP, et al. Evaluation of serum adenosine deaminase as a tumor marker in gastric cancer. Res J Medicine Med Sci. 2009;4(2):411-14.
Simard EP, Torre LA, Jemal A. International trends in head and neck cancer incidence rates: differences by country, sex and anatomic site. Oral Oncol. 2014;50(5):387-403.
Vigneswaran N, Williams M. Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral Maxillofac Surg Clin North Am. 2014;26(2):123-41.
Alam MS, Siddiqui SA, Perween R. Epidemiological profile of head and neck cancer patients in Western Uttar Pradesh and analysis of distributions of risk factors in relation to site of tumor. J Can Res Ther. 2017;13(3):430-5.
Waltonen J, Ozer E, Hall N, Schuller D, Agarwal A. Metastatic carcinoma of the neck of unknown primary origin: evolution and efficacy of the modern workup. Arch Otolaryngol Head Neck Surg. 2009;135(10):1024-9.
Ashok KJ, Pinto GJO, Kavitha AK, Palathra MJ. The Diagnostic and prognostic value of serum adenosine deaminase levels in head and neck cancer. J Clin Diag Res. 2008;2(3):833-7.
Lal H, Munjal S, Wig U, Saini A. Serum enzymes in head and neck cancer III. J Laryngol Otol. 1987;101(10):1062-5.
Mishra R, Agarwal MK, Chansuria JP. Serum adenosine deaminase levels as an index of tumor growth in head and neck malignancy. Indian J Otolaryngol Head Neck Surg. 2000;52(4):360-3.
Sharma S, Desai P, Metgudmath R. Evaluation of serum adenosine deaminase and retinol in patients with laryngeal cancer. Indian J Pharma Biol Res. 2013;1(04):30-4.
Chandrakiran C, Jogy T, Patil S. Serum adenosine deaminase levels and human papillomavirus as prognostic and predictive factors for laryngeal and pharyngeal carcinomas. Indian J Otolaryngol Head Neck Surg. 2018;71(S1):522-7.
Rai B, Kaur J, Jacobs R, Anand S. Adenosine deaminase in saliva as a diagnostic marker of squamous cell carcinoma of tongue. Clin Oral Investig. 2010;15(3):347-9.
Canbolat O, Akyol O, Kavutcu M, Isik A, Durak I. Serum adenosine deaminase and total superoxide dismutase activities before and after surgical removal of cancerous laryngeal tissue. J Laryngol Otol. 1994;108(10):849-51.
Dhankhar R, Dahiya K, Sharma TK, Ghalaut VS, Atri R, Kaushal V. Diagnostic significance of adenosine deaminase, uric acid and C-reactive protein levels in patients of head and neck carcinoma. Clin Lab. 2011;57(9-10):795-8.
Sharma S, Desai PB, Metgudmath RB. Role of purine metabolic enzymes and vitamin A in patients with oral cancer. Int J Pharm Biol Chem Sci. 2013;2 (4):31-7.
